Skip Navigation


JAC Advance Access originally published online on May 5, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/6/895    most recent
dkh239v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ahlenstiel, G.
Right arrow Articles by Spengler, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahlenstiel, G.
Right arrow Articles by Spengler, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 895-898
© 2004 The British Society for Antimicrobial Chemotherapy

Leading Article

CC-chemokine receptor 5 (CCR5) in hepatitis C—at the crossroads of the antiviral immune response?

Golo Ahlenstiel, Rainer P. Woitas, Jürgen Rockstroh and Ulrich Spengler*

Department of Internal Medicine I, Rheinische Friedrich Wilhelms Universität Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany

An effective immune response to hepatitis C virus (HCV) infection requires efficient recruitment and activation of inflammatory cells to the liver, the site of infection. Chemokines are critically involved in this process, since they exert both chemotactic and immunoregulatory actions. In particular, the interaction between chemokines CCL3 (MIP-1{alpha}), CCL4 (MIP-1ß) and CCL5 (RANTES) and their receptor, CC-chemokine receptor 5 (CCR5), may be critical in regulating T cell functions by mediating recruitment, polarization, activation and differentiation of antiviral type 1 cytokine secreting T helper and cytotoxic T cells. A 32 bp deletion in the encoding region of CCR5 leads to complete loss of the functional CCR5 receptor in subjects homozygous for this mutation and decreased expression in heterozygous patients. This fact provides the unique opportunity to study the role of the CCR5 receptor in chronic hepatitis C infection by comparing immune responses between HCV infected CCR5-{Delta}32 carriers and CCR5 wild-type patients. This article will summarize and discuss the available data with respect to possibly altered disease susceptibility, clinical course and treatment outcomes associated with the CCR5-{Delta}32 mutation in hepatitis C.

Keywords: HCV, T lymphocytes, mutations

* Corresponding author. Tel: +49-228-287-6789; Fax: +49-228-287-9822; E-mail: spengler{at}uni-bonn.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
M. M. Lederman, A. Penn-Nicholson, M. Cho, and D. Mosier
Biology of CCR5 and its role in HIV infection and treatment.
JAMA, August 16, 2006; 296(7): 815 - 826.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.